Speakers

Jing Liu
PhD. Co-founder of ACMES, Board member and Senior advisor.

Dr. Liu is a licensed acupuncturist and herbalist. He was a physician in China, major in integrative medicine and he also has PhD degree. He has his private clinical practice also at The Marino Center at Cambridge. Dr. Liu has be a research fellow at MGH since 1995. His research interest has been focused on Inflammation and Cancer with integrative approaches.

Nezam H. Afdhal

Nezam H. Afdhal, md, is Chief of Hepatology and director of the Liver Center at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He is also Professor of Medicine at Harvard Medical School. Dr. Afdhal received his MD degree in 1981 from the Royal College of Surgeons in Ireland and did fellowship training at University College Dublin and at Boston University School of Medicine. Dr. Afdhal’s clinical expertise focuses on the management of the complications of liver disease, including cirrhosis and portal hypertension. He is the director of a clinical trials group focusing on novel treatments of hepatitis B and C, liver fibrosis and NASH. Additional research interests include basic and translational research in gallstone disease, liver cancer and in liver fibrosis. His research is funded by multiple NIH, industry and foundation grants. Dr. Afdhal has served on multiple State and National advisory boards for liver disease. He has served as on the Editorial Board and as a reviewer for multiple journals. He has published more than 180 papers in journals such as New England Journal of Medicine, Gastroenterology, Hepatology, Gut, and Journal of Hepatology, as well as 30 book chapters and 2 books. He is the editor for the Journal of Viral Hepatitis. He has spoken nationally and internationally on chronic liver disease and received many awards, including the American Liver Foundation Award for Excellence, a Fullbright Scholarship and the Mitchell Lectureship of the Royal College of Physicians. He is a member of the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the European Association for the Study of the Liver.

Richard C. Laudon

Richard C. Laudon, O.D. is a tenured Associate Professor at the New England College of Optometry and an attending at the New England Eye, Commonwealth. He is the Coordinator of their Vision Therapy Services. Dr. Laudon graduated from the New England College of Optometry and has been a full time member of their faculty for over thirty-nine years. Dr. Laudon is a known authority on visual related learning problems and vision therapy. He has lectured throughout the United States of America as well as Spain, Italy, Germany and Columbia on topics related to his expertise. Dr. Laudon has also published numerous articles and chapters in his areas of interest.

Gloria Y. Yeh

Gloria Y. Yeh is Assistant Professor of Medicine at Harvard Medical School and a clinician investigator in the Division of General Medicine and Primary Care at Beth Israel Deaconess Medical Center (BIDMC). She received her medical degree from the University of Maryland and her MPH from the Harvard School of Public Health. Her major research activities involve the investigation of safety, efficacy and mechanisms of mind-body exercise for chronic disease, with a particular interest in cardiopulmonary conditions, and expertise in clinical trial design of mind-body therapies. She is principal or co-investigator on multiple trials funded by the NIH, including two R01's investigating tai chi for patients with COPD. Dr. Yeh is the Director of the NIH T32-funded Harvard Medical School Research Fellowship in Integrative Medicine. Her clinical work is in the primary care practice at BIDMC, Healthcare Associates, and the Cheng and Tsui Center for Integrative Medicine at BIDMC.

Buchbinder, Elizabeth

Buchbinder, Elizabeth I., MD: Dr. Buchbinder is an attending oncologist on staff at Beth Israel Deaconess Medical Center; she is a clinical instructor of Harvard medical school. She received her medical training at Tufts Medical School, and finished her medical residency and oncology fellowship at Beth Israel Deaconess Medical Center. Dr. Buchbinder is an oncologist with primary clinical interests in head and neck oncology, melanoma, and hepatobiliary and pancreatic cancers. As a recipient of the American Society of Clinical Oncology (ASCO) Young Investigator Award, she continues to perform translational research in oncology.

Martha Herbert
MD, PhD

Dr. Herbert is Assistant professor of neurology at Harvard Medical School and a pediatric neurologist at Massachusetts General Hospital, where she is the director of the TRANSCEND Research Program. She is an affiliate of the Harvard-MGH-MIT-HST Martinos Center for Biomedical Imaging. Dr. Herbert earned her medical degree at the Columbia University College of Physicians and Surgeons. Prior to her medical training she obtained a doctoral degree at the University of California, Santa Cruz, studying evolution and development of learning processes in biology and culture in the History of Consciousness program, and then did postdoctoral work in the philosophy and history of science. She trained in pediatrics at Cornell University Medical Center and in neurology and child neurology at Massachusetts General Hospital, where she has remained. She received the first Cure Autism Now Innovator Award and is on the Scientific Advisory Committee of Autism Speaks. She is active collaborator, speaker and executive member of ACMES and to cure autism institute.

William Stone
PhD, ABPP-CN

William Stone, PhD, ABPP-CN, Dr. Stone is Director of Neuropsychology Training and Clinical Services, Massachusetts Mental Health Center (MMHC); Director of Neuropsychology Fellowship Program at MMHC and Beth Israel Deaconess Medical Center (BIDMC); Assistant Professor of Psychology, Harvard Medical School, staff clinical psychologist of department of psychiatry, BIDMC. His research is focused on identifying cognitive, clinical and biological risk factors for the development of psychiatric illness. These efforts emphasize attempts to identify liability syndromes for schizophrenia and related disorders. They also aim to develop interventions that will alter or prevent the trajectory to psychosis and other manifestations of major mental illness. He is executive committee member of ACMES and editor of North American Journal of Medicine and Science.

Douglas Levine

Douglas Levine, MD: Dr.Levine is Vice President, Medical Scientific Affairs, Ironwood Pharmaceuticals, and is leading this function’s integrated support of development and commercialization of linaclotide and additional medicinal products in the company’s portfolio. Previously, Dr Levine was Executive Medical Director for US Managed Markets and US Development Brand Leader for Nexium (esomeprazole) at AstraZeneca. His experience in industry has been to strategically integrate clinical outcomes, health economic, and quality of life evidence with commercialization of medicinal products via consumer, health care professional, and managed markets customer channels. Prior to entering the pharmaceutical industry, Dr Levine was Associate Professor in the Division of Gastroenterology, Department of Medicine, of the University of Washington where his professional activities included teaching, clinical care, and applied clinical sciences focused on translational research on stratification of patients at risk for gastrointestinal malignancies and experimental therapeutics for patients with inflammatory diseases of the alimentary tract. He is a Fellow of the American College of Gastroenterology.

Pages